John Weinberg, MD, COO, Veloxis Pharmaceuticals, describes the benefits of the Veloxis’ Envarsus, an orphan drug for the treatment of organ transplant rejection. Envarsus is a reformulation of tacrolimus, the current gold standard of treatment. The new drug breaks down the bonds of the active molecule, resulting in faster, more effective absorption in the gut lining, and ultimately, lower dosing needed to yield the same effect. Since it is a true once-daily medication, Envarsus will improve patient compliance through reducing the number of pills patients have to take, in addition to minimizing the quantity of a toxic medication a patient must ingest.